6 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Within triple-negative breast cancer, the mesenchymal research profile describes expression linked to motility and differentiation. It is distinct from claudin-low biology or metaplastic histology and does not mean resistance to every drug.
Lehmann's M and MSL profiles shared epithelial-to-mesenchymal transition and growth-factor-related expression; representative cell models responded to specified agents in the 2011 experiments. The 2016 refinement retained M while accounting separately for the substantial stromal contribution to MSL. Model sensitivity and an RNA programme do not establish universal clinical sensitivity or resistance.
Claudin-low and metaplastic are different descriptors. The 2010 claudin-low work described low luminal-differentiation expression with immune, stromal and stem-like features. Fougner's 2020 re-analysis described a phenotype that can occur across intrinsic subtypes, not a label interchangeable with Lehmann M. Metaplastic carcinoma is a histological diagnosis with its own variants. These descriptions can overlap without being identical.
| Setting | Approach | Guideline |
|---|---|---|
| Stage II to III and metastatic | As for triple-negative disease; no mesenchymal-specific treatment is approved. PI3K/mTOR inhibitors and dasatinib were active in cell lines only. | not mapped |